China: Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer
For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published online May 1 in The Journal of Urology.
Hongyang Qian, from Shanghai Jiao Tong University, and colleagues conducted a randomized trial recruiting 141 patients with locally advanced, high-risk prostate cancer who were randomly assigned to the NCHT group (who received docetaxel plus androgen deprivation therapy for six cycles) or the neoadjuvant hormone therapy (NHT) group (who received androgen deprivation therapy for 24 weeks) in a 2:1 ratio. Three-year bPFS was examined as the primary end point.
Source: Advances and More licensed by HealthDay
